- North Korean Threats And The Cytori - BARDA Stem Cell Collaboration
- Cytori's EU Approval For Intravase - Intentionally Downplayed?
- Worth The Wait: Implications Of Cytori Therapeutics' $106 Million BARDA Contract
- Merge Healthcare Puts Itself Up For Sale
- Osiris Stem Cell Drug Approval Bodes Well For Athersys
Wall Street Titan
ABOUT
Spent my entire 28 year career on Wall Street. First 12 years at Bear Stearns (6 years in Regulatory Accounting and 6 years as an Associate Director in Derivatives and Program Trading). The remainder of my career was spent as the CFO of a small broker/dealer. Since 2008 I've been investing and trading my own portfolio, full time,
SNAPSHOT
- Description: Full time investor. Trading frequency: Weekly
- Interests: Bonds, Dividend stock ideas & income, Stocks - long, Stocks - short
COMPANY
Currently, there is no company profile for Wall Street Titan.
Book
Currently, there are no book details for Wall Street Titan.
LATEST STOCKTALK
more »
CRM breaking down. Falling through support level of $110. Could go much lower.
Nov 22, 2011
Latest Comments
more »
Latest comments on Wall's Articles
LATEST ARTICLES & INSTAPOSTS
more »